Sustained Release Selective Androgen Receptor Modulator for the Treatment of Chronic Pain

New therapeutic that offers lasting relief without addiction. Does not induce typical androgen receptor side effects. Microparticle formulation maintains stable blood levels over prolonged period.
  • New therapeutic that offers lasting relief without addiction.
  • Does not induce typical androgen receptor side effects.
  • Microparticle formulation maintains stable blood levels over prolonged period.

Abstract:

Technology Description

Chronic pain affects up to 50 million U.S. adults each year, according to the CDC. Many pathological conditions such as fibromyalgia, multiple sclerosis, cancer, arthritis, or physical trauma can cause chronic pain. For severe long-lasting chronic pain, clinicians may turn to opioids to help patients’ manage their pain. Unfortunately, these drugs carry considerable risk even when used short-term and are highly addictive. New therapeutics that offer long-lasting relief without significant side effects or addictive qualities will be invaluable for the treatment of chronic pain.

Inventors at the University of Iowa have developed a sustained-release selective androgen receptor modulator (SARM) formulation for the treatment of chronic pain. SARMs are small molecules that can exert varying tissue-specific effects on androgen receptors by inducing the anabolic effect of testosterone while minimizing the androgenic effects. The inventors have discovered that the administration of SARMs can protect both males and females against widespread musculoskeletal pain in an animal model of fibromyalgia. They have further developed a sustained release SARM-loaded microparticles that will maintain stable blood levels over a prolonged period and significantly improve convenience for the patient, and thus compliance to treatment.

Stage of Development

The microparticle formulation has been developed and validated using a rodent model of fibromyalgia and widespread pain.

Advantages:

Long-lasting sustained formulation; better patient compliance

No typical androgen receptor side effects

Non-opioid target; likely non-addictive

Potential Applications:

-

Additional Information:

-

Contact Information:

  • Name : Mihaela D. Bojin
  • Title :
  • Department :
  • Email : mihaela-bojin@uiowa.edu
  • Phone : 319-335-2723
  • Address :